Ultimovacs - Prostate cancer trial patient enrollment complete
Ultimovacs has announced the completion of patient enrollment in the Phase I TENDU study in prostate cancer. This trial will use the company’s proprietary Tetanus-Epitope Targeting (TET) adjuvant platform, which is a technology with a new mechanism of action. In total 12 patients have now been treated with Ultimovacs’ vaccine in the trial, which will provide information on the platform’s safety and ability to activate patient immune systems towards tumours at different doses. We see this as positive news for Ultimovacs, as it continues to leverage its immunology expertise to develop novel oncology treatments. Following several enrollment and data milestones from its UV1 development programme in 2022, we anticipate that Ultimovacs will have a period of enriched newsflow in 2023–24. We value the company at NOK7.9bn or NOK231 per share.Ultimovacs ASA Formerly known as Ultimovacs AS. Ultimovacs ASA, formerly Ultimovacs AS, is a Norway-based pharmaceutical company developing immunotherapies against cancer. The Company's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action. The Company is performing a broad clinical development program with clinical trials in Europe and the USA.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.